A phase II trial evaluating enzalutamide plus exemestane versus exemestane monotherapy (NCT02007512) [108] showed that this combination was well tolerated in patients with ERα-positive and/or PR-positive breast cancer. This evidence concerns the gene ESR1 and breast cancer.